Volume 1

Issue 1

Article 8

Investigate the seminal plasma biomarkers in differentiation between
obstructive- and non-obstructive azoospermia
Naael H Ali
College of Medicine, University of Basrah, Basrah, Iraq, naael.ali@uobasrah.edu.iq

Abdulkareem M Jewad
Department of Medical Laboratory Technology, College of Health and Medical Technology, Southern Technical
University, Basrah, Iraq

Attayia K Attayia
Department of Medical Laboratory Technology, College of Health and Medical Technology, Southern Technical
University, Basrah, Iraq

Follow this and additional works at: https://majms.alkafeel.edu.iq/journal

Recommended Citation
Ali, Naael H; Jewad, Abdulkareem M; and Attayia, Attayia K (2022) "Investigate the seminal plasma biomarkers in
differentiation between obstructive- and non-obstructive azoospermia," Maaen Journal for Medical Sciences: Vol. 1 :
Iss. 1 , Article 8.
Available at: https://doi.org/10.55810/2789-9128.1007
This Original Study is brought to you for free and open access by Maaen Journal for Medical Sciences. It has been accepted for
inclusion in Maaen Journal for Medical Sciences by an authorized editor of Maaen Journal for Medical Sciences.
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Abstract
Background: Azoospermia is a very severe form infertility in males. Today, clinicians depend on semen analyses for the
prediction of the reproductive potential of males, and testicular biopsies are the only reliable methods for diagnosing
various subtypes of azoospermia. In the recent times, advances in proteomics contributed to look for new infertility biomarkers in males whose seminal plasma proteins are rich with proteins of various genital tract origins. Therefore, the ﬁelds
of proteomics helped to develop new infertility biomarkers in males. Extracellular Matrix Protein 1 and Seminal plasma
proteins Testis Expressed Protein 101 assays currently existing of are under the last development for the purpose of clinical
uses. Therefore, this study aimed to assesses the capability of Testis Expressed Protein 101 and Extracellular Matrix Protein
1, Seminal Plasma proteins, for differential diagnosing between Obstructive azoospermia from non-obstructive azoospermia by noninvasive methods. A case control study was conducted on 40 infertile azoospermia males who were clinically
examined, having their seminal ﬂuid analyzed and hormonally investigated and SP proteins Testis Expressed Protein 101
and Extracellular Matrix Protein 1 were assessed. Other ﬁfty healthy fertile men were included as control group.
Results: The studied biomarkers were signiﬁcantly lower in non-obstructive azoospermia then Obstructive azoospermia were had higher level, and the control group participants were higher than the others.
Conclusion: Extracellular Matrix Protein 1 and Testis-expressed 101 protein should combined and could make a differences between non-obstructive azoospermia and obstructive azoospermia thus eliminating most of the diagnostic
testicular biopsies. Seminal plasma needs for pre-treatment before processing for diagnose any biomarker specially to
differentiate between obstructive azoospermia and non-obstructive azoospermia. By the cutoff value of 2.3 mg/ml for
Extracellular Matrix Protein 1 obstructive azoospermia and normal spermatogenesis are distinguished with 100%
speciﬁcities, and obstructive azoospermia from non-obstructive azoospermia with 73% speciﬁcities, 100% sensitivities.
Yet Testis Expressed Protein 101 lack could help distinguishing the non-obstructive azoospermia in speciﬁcs.
Keywords: Azoospermia, Obstructive azoospermia, Non-obstructive azoospermia, TEX101, ECM1

1. Introduction
en are responsible for more than ﬁfty percent
of infertility cases among couples suffering
from infertility worldwide. These cases range from
oligozoospermia to azoospermia, which is diagnosed in about two percent infertile men in the
general population [1]. Two forms of azoospermia;
non-obstructive azoospermia (NOA) and obstructive azoospermia (OA). The main cause for the ﬁrst
is results from pathological changes in epididymis
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or congenital anomalies because of the physical
obstructions in reproductive tracts [2], while the
NOS is failure of testicular function in production of
sperms, sub classiﬁed, according to the testicular
tissue histopathological examinations, into; maturation arrest (MA) hypospermatogenesis (HS); and
Sertoli celleonly syndrome (SCO) [3,4]. Currently,
the invasive, surgical procedure (testicular biopsy) is
the only deﬁnitive diagnostic method to distinguish
between OA and NOA. Also it is used to identify the
NOA subtypes. However, this invasive approach for
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differentiating OA from NOA by surgical examinations of random testicular tissues could not be an
accurate reﬂection of the NOA histopathology as
spatial distributions of spermatogenesis. Also
testicular biopsy procedure may have possible
complications such as; tissue damage; evoke of antisperm antibodies; bleeding; and chronic pain. It
may need for more than one surgical procedure.
A marker test for differentiation of azoospermia
patterns, that is noninvasive, is an unmet need in
infertility treatment. Such test could reduce testicular biopsy, provide more accurate assessment of
histopathological patterns, and facilitate better
planning for assisted reproduction. Some biomarkers are already delivered [5]. Yet, there is a
need to new biomarkers with better diagnostic
sensitivities for the differentiation between hypospermatogenesis, maturation arrests, and Sertoli
cell-only syndromes of NOA.
The SP is utilized as a non-invasive and suitable
clinical samples to diagnose disorders in reproductive system of males. Seminal plasma (SP) proteomic analyses and/or spermatozoa could supply data
in terms of presence and abundance of proteins
(biomarkers) and its post-translational modiﬁcations. It was found that SP is made of 3200 proteins
from different genital organs [6]. In the same year
(2013) Rolland AD with his collogues [7] found
about 2545 distinct proteins in the SP of human.
Then they proﬁled the gene expression of the
candidate protein markers, 83 in testis, 42 in
epididymis, 7 in seminal vesicle and 17 in prostates.
The stringent blood-testis and blood-epididymis
barriers make these biomarkers not found in other
parts of the body. Thus, SP from seminal ﬂuid is still
the only available ﬂuids for the non-invasive diagnosis of male infertility [8]. TEX- 101 (Testisexpressed sequence 101 protein) is a membrane
glycoprotein. Additionally, its speciﬁc expression in
germ cells with no expressions in other tissues and
cells may cleave from the spermatozoa surfaces and
releasing into seminal plasma when the sperm
maturate into epididymis, and ECM1 (Extracellular
matrix protein 1), known as main infertility biomarkers in males [9].
In the present study we aimed to evaluate the
diagnostic ability of TEX101 and ECM1 biomarkers
to distinguish (noninvasively) between OA and
NOA in view of set of seminal hormones used for
azoospermia patients.

2. Materials and methods
Study population: A total of forty infertile men
with azoospermia (normal female partner) were
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enrolled in this case control study through July, 2021
to Jan, 2022. They were diagnosed after testicular
biopsy surgery and histopathology exam were done
to diagnose obstructive azoospermia or nonobstructive azoospermia. Twenty of them with
obstructive azoospermia aged (25e50) years and the
others with non-obstructive azoospermia aged
(22e51) years. Other ﬁfty fertile men aged (19e50)
years, were enrolled in the study as control group.
The patients were referred to the Infertility center,
Basrah Teaching Hospital, Basrah, Iraq.
Samples and processing: Routine semen analyses
was performed according to the Stander method
recommended by the World Health Organization
[10]. Samples were left for 20e60 min for liquefaction to occur. Then semen quality was evaluated by
using two parameters: macroscopically and microscopic examination.
All patients examined in details for the identiﬁcation of the etiology of azoospermia, such as the
history, physical investigation, semen analysis.
Semen hormone proﬁle (FSH, LH, Testosterones,
Prolactin, Melatonin, ECM1, TEX 101, AMH).
Audiologist with the help of an orchidometer to
calculate the bilateral testicular size.
In case of Azoospermia, samples with sperm
count was zero reference limit were used. Samples
of related conditions, such as oligoasthenozoospermia, oligoasthenoteratozoospermia or oligoteratozoospermia were excluded.
TEX101 and ECM1 level measured by ELISA Kits
(Bioassay Technology Laboratory, China, Cat. No:
E4614Hu). Seminal hormones levels were by
enzyme linked ﬂuorescent assay kits (VIDAS®,

BIOMERIEUX,
France, catalog number 417011).

3. Ethical issue, approval and ofﬁcial
permission
Prior to data collection, we obtained a signed
consent from all participants on the explanation of
the aims of the work ensuring data privacy.
To conduct the present study, the protocol was
reviewed and approved from the Basrah Health
Department, Ministry of Health. The permission
was obtained from them.
3.1. Statistical analysis
The SPSS software for windows, version 26 was
used to analyse the data. The data of the current
work was nonparametric. So, the statistical methods
match the data. The descriptive statistics were median to the quantitative data, frequencies and percentages (%) based on the kinds of the variables. We

48

MA'AEN JOURNAL FOR MEDICAL SCIENCES 2022;1:46e52

used Chi-square and Fishers Exact Test for the
comparison of the proportion and frequencies and
Kruskal Wallis Test for the comparison of the median of various investigation groups, signiﬁcance
level (P value) of 0.05 is signiﬁcant. We used
Spearman Test was to ﬁnd correlations between
variables.

Table 2. Descriptive and differences of TEX101 and ECM1 in patients
and control groups.
Test
ECM1
(mg/ml)
TEX101
(ng/ml)

Median
Min-Max
Median
Min-Max

OA
(20)

NOA
(20)

Control
(50)

p-value

21
4e45
97
78e125

1.75
1e3
6.25
3e7

44.5
31e61
342.0
127e376

P < 0.05
P < 0.05

4. Results
No signiﬁcant differences (P > 0.05) were found
between three groups of the study in age and all
seminal hormones (FSH, LH, testosterone, and
prolactin), while there was signiﬁcant difference (P
˂0.05) in AMH and melatonin hormones (Table 1).
Table 2 shows the descriptive (median, minemax)
and statistical differences of TEX101 and ECM1 in
patients and control groups. Signiﬁcant difference
between groups in TEX101 and ECM1 were resulted. Its shows that healthy control group had higher
level of these markers while the NOA were in the
lowest level.
Table 3 shows the Spearman's correlations between age, hormones, and seminal biomarkers
TEX101 and ECM1 in NOA patients group.
Resulted that FSH correlated with melatonin
(R ¼ 0.511, P ¼ 0.021), and with TEX101 (R ¼  0.501,
P ¼ 211) (Fig. 2). Testosterone with ECM1 (R ¼ 0.503,
P ¼ 0.024) (Fig. 1).
Table 4 shows the Spearman's correlations between age, hormones, and seminal biomarkers
TEX101 and ECM1 in OA patients group. Resulted
that only prolactin correlated with age (R ¼ 473,
P ¼ 0.035).
Table 5 shows the results of histopathological
investigation for NOA subtypes.

5. Discussion
Considerable percent of infertility cases in men
remain unknown, despite the evoked factors on
male reproduction including environmental, genetic, and life styles. Defective in spermiogenesis
when found in the routine semen analysis which
reveal no spermatozoa in semen, a case known as
azoospermia.
About 2e8% of males with fertility deﬁcits show
azoospermia [4] due to an obstructed or discontinuous of male genital tract (OA) or a failure of the
testis to start or keep spermatogenesis because of
the endogenous or exogenous abnormalities (NOA).
In view of limited diagnostic tools, always depends on a standard semen analysis. So the patients
and clinicians require extra diagnostic biomarkers.
Seminal plasma components originate from many
sites in the male reproductive tract. It is harbor
shedding antigens of sperms and provides a nutritive and protective milieu.
In the current study the azoospermia diagnosis by
high-powered microscopic tests of centrifuged
seminal ﬂuids on at least two cases. Then the patients with azoospermia were evaluated for identifying the etiology of the patient's condition. For
exclusion criteria, complete medical history

Table 1. Descriptive and statistical differences of age and hormonal proﬁle in azoospermic patients and control groups.
Test
Age
FSH
AMH
LH
Testosterones
Melatonin
Prolactin
a

Median
Min-Max
Median
Min-Max
Median
Min-Max
Median
Min-Max
Median
Min-Max
Median
Min-Max
Median
Min-Max

Signiﬁcant by KruskaleWallis Test.

NOA (20)

OA (20)

Control (50)

p- value

34.0
22e50
3.4
1.3e3.8
0.2
0.08e0.89
2.3
0.63e2.90
2.5
1.3e3.8
25.5
17e34
11.8
10.3e13.0

35.5
25e50
2.5
2.13e4.8
0.15
0.1e0.33
1.7
1.2e4.4
4.25
3.6e4.9
32.5
23e42
8.1
7.4e11.6

33.0
19e15
2.2
1.8e5.7
0.64
0.21e0.99
1.3
0.12e1.90
4.2
3.60e4.90
39
34e48
9.63
6.5e10.9

P > 0.05
P > 0.05
P < 0.05a
P > 0.05
P > 0.05
P < 0.05a
P > 0.05
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Table 3. Spearman's correlations between age, hormones, and seminal biomarkers in NOA patients group.
Patient group
Non-Obstructive
Azoospermia

Age (year)
FSH
AMH
(ng/ml)
LH
Testosterone
(ng/ml)
Prolactin
(ng/ml)
Melatonin
(Pg/ml)
ECM1
(mg/ml)

R
Sig.
R
Sig.
R
Sig.
R
Sig.
R
Sig.
R
Sig.
R
Sig.
R
Sig.

FSH

AMH
(ng/ml)

LH

Testosteron
(ng/ml)

Prolactin
(ng/ml)

Melatonin
(Pg/ml)

ECM1
(mg/ml)

TEX 101
(ng/ml)

.429
.059

.280
.231
.031
.895

.036
.881
.039
.869
.089.708

.142.549
.440
.052
.019.938
.305
.191

.293
.210
.012
.959
.201
.395
.218
.356
.004
.987

.190
.422
.511
.021*
.126
.596
.098
.681
.219
.354
.098
.680

.197
.405
.069
.771
.196
.408
.346
.135
.503
.024*
.106
.656
.325
.162

.175
.459
.501
.0211*
.276
.239
.444
.050
.388
.071
.155
.515
.396
.084
.249
.290

includes; childhood diseases such genital trauma or
prior pelvic or inguinal surgery; as viral orchitis or
cryptorchidism; radiation exposure therapy/
chemotherapy and infections including epididymitis
or urethritis; a very late fever or heat exposure and
current medications; and family past records.
Physical examination includes; testis sizes (normal
testis volume greater than 19 ml) and consistency;
secondary sex characteristics; and consistent vasa
differentia and epididymides; a varicocele; and
masses on digital rectal tests. For hormone examination, seminal plasma level of hormones was
measured by enzyme linked ﬂuorescent assay kits

(VIDAS®, BIOMERIEUX,
France) which have high

sensitivity. All This initial evaluation work was done
to clarify the underlying cause of the azoospermia,
and whether this cause of azoospermia is amenable
to therapy. The evaluation for causes results were
divided into: pre-testicular, testicular and posttesticular. Endocrine abnormalities were the cause
for pretesticular causes of azoospermia [11]. Disorders of spermatogenesis related to testicular etiologies, while post-testicular etiologies were due to
either ejaculatory dysfunction or obstruction of
sperm delivery to the urethral meatus. The last
cause we found in 40% of azoospermia patients.
Because it is a protein which epididymis discharges
in the semen mainly, the ECM1 biomarkers is used

Fig. 1. Regression ﬁgure of testosterone and ECM1 in NOA patients.
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Fig. 2. Regression ﬁgure of FSH and TEX101 in NOA.

to different NOA from OA. Similarly, proteins
which have speciﬁc expressions in testis include
TEX101 appearing as biomarkers for NOA [11].
In the result of the present study, the biomarkers
ECM1 and TEX101 were differ signiﬁcantly (P ˂
0.05) between the three studded groups, the median
of each biomarker was higher in healthy control
group than OA and NOA group level [12]. Many
researchers resulted by a seminal plasma proteomic
analyses show no speciﬁc proteins to operate the
sperms and proteins in azoospermia patients like
both ECM1 and TEX101 seminal plasma levels of
with high signiﬁcance in males with NOA than
males having OA [13]. According to other

researchers [14], TEX101 alone was no strong
markers for the non-invasive differentiation of NOA
from OA (32% sensitivity and 99% speciﬁcity). Thus,
combining epididymis-speciﬁc protein ECM1 and
TEX101 may help differentiating NOA from OA and
thus eliminating most diagnostic testicular biopsies.
Furthermore, identifying the speciﬁc proteins from
testis or from germ cell which spermatocytes,
spermatids, or spermatozoa discharge into semen
exclusively could be a provider of markers to accurately show the stages of spermatogenesis. These
ﬁndings agree with other scholars [9,15,16], reporting that testis-expressed protein 101 as the
biomarker for azoospermia and extracellular matrix

Table 4. Spearman's correlations between age, hormones, and seminal biomarkers in OA patients group.
Type of disease
Obstructive
Azoospermia

Age (year)
FSH
AMH
(ng/ml)
LH
Testosteron
(ng/ml)
Prolactin
(ng/ml)
Melatonin
(Pg/ml)
ECM1
(mg/ml)

R
Sig.
R
Sig.
R
Sig.
R
Sig.
R
Sig.
R
Sig.
R
Sig.
R
Sig.

FSH

AMH
(ng/ml)

LH

Testosteron
(ng/ml)

Prolactin
(ng/ml)

Melatonin
(Pg/ml)

ECM1
(mg/ml)

TEX 101
(ng/ml)

.108
.652

.103
.666
.255
.278

.061.797
.047.844
.280
.233

.230.329
.275.241
.004
.988
.147
.536

.473
.035
.080
.737
.139
.560
.190
.423
.113
.635

.280
.232
.253
.282
.112
.639
.087
.715
.048
.840
.317
.173

.348
.132
.088
.712
.052
.829
.165
.487
.047
.843
.069
.771
.103
.667

.062
.796
.136
.566
.022
.926
.183
.439
.081
.734
.006
.981
.081
.733
.068
.776

.
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Table 5. Histopathological investigation for NOA patients.
Histopathological Exam

NOA

%

Sertoli celleonly syndrome
maturation arrest
hypospermatogenesis
Mixed
TOTAL

3
5
6
6
20

15
25
30
30
100

protein 1 differentiating NOA and post-vasectomy
males with threshold values of 2.3 ng/mL.
Angiotensin-converting enzyme (ACE) TEX 101
regulation on spermatozoa and removing GPIanchored protein played a vital role in the production of fertile spermatozoa, and ACE operation did
no rely done its well-known peptidase activities.
This means TEX101 has unique speciﬁc substrate
providing a potential targets to produce an awaited
contraceptive medicines for males [17].
It is worthy to mention her that SP was not
traditional to clinically diagnose as it may hamper
the immunoassay performances because it has
molecules features including fast protease-mediated
liquefactions, high viscosity, and big quantity of
seminal macrovesicles [3]. So, SP could require
more treatment procedures for facilitating the
quantiﬁcation of the protein with high sensitivities.
For enhancing ELISA sensitivities, multiple combinations of detergents, temperatures, and pH values
are required for the selection of two SP pretreatment protocols: treatment of seminal plasma with
guanidinium at pH 12 or deoxycholate at 63  C may
lead to the release of TEX101 from its vesicles [18].
Other authorities noticed in the present study that
ejaculatory dysfunction or ejaculatory duct
obstruction may be found in those with azoospermic
with normal sized testes and low semen volume.
Therefore, the FSH is useful and critical factors to
determine of diagnostic testicular biopsies are
required for establishing the existence or lack of
normal spermatogenesis [13]. If FSH elevated two
times than normal limit, abnormal spermatogenesis
is the diagnosis. Thus, diagnostic testicular biopsies
are not required these patients. Yet, if sperm retrievals with ICSI are taken into account, a testicular
biopsies could be conducted for prognostic aims, for
determining if spermatozoa which could possibly
retrieved by later testicular sperm aspirations or
extractions [19].
Signiﬁcant difference in AMH in three studied
groups, The NOA have very low seminal plasma
concentration. It is well known that AMH produced
by Sertoli cells and it is responsible for the regression of Mullerian ducts in male embryo. Yet, AMH
mutations or its speciﬁc receptors in humans, or
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disruptions of these genes in rodents showed no key
function(s) for postnatal AMH actions. Persistent
Mullerian duct syndrome is very uncommon in
male pseudo-hermaphroditism with continues
occurrence in Mullerian derivations in otherwise
usually virilized men [20]. Therefore, it is suggested
that there are relationships between AMH secretion
relation with, Sertoli cell function, a seminal marker
for spermatogenesis [21]. In addition, there was a
positive correlation between the total AMH contents
in seminal plasma with sperm concentrations and
number. However, the reports in healthy males on
the relationship between spermatogenic parameters
and circulations of AMH levels are not consistent,
and post pubertal AMH secretion is still no clear
requiring other examinations.
It is recommended here that assays for ECM1 and
TEX101 could replace the majority of the diagnostic
testicular biopsies facilitating the predicting sperm
retrieval procedure results. So, the increase in the
reliabilities and successes of helped reproduction
approaches.

6. Conclusion
Combining extracellular matrix protein 1 (ECM1)
and testis-expressed sequence 101 protein (TEX101)
may help to make a difference between NOA and
OA. It this help in eliminating most diagnostic
testicular biopsies. Seminal plasma required pretreatments pre-processing for diagnosing any
biomarker special for the differentiation between
OA and NOA.
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